Clinical Trials
2 trialsNCT03225716 2024-05-03
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02666209 2017-08-28
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Dana-Farber Cancer Institute
No longer available